The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Bristol-Myers Squibb; Celgene; Genentech; Lilly; Novartis
Early clearance of plasma EGFR mutations as a predictor of response to osimertinib in the AURA3 trial.
 
Frances A. Shepherd
Stock and Other Ownership Interests - AstraZeneca; Lilly
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Merck Serono; Merck Sharp & Dohme; Roche/Genentech
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Lilly; Merck Serono
Research Funding - AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); Merrimack (Inst); Pfizer (Inst); Roche Canada (Inst)
 
Vassiliki Papadimitrakopoulou
Consulting or Advisory Role - ARIAD; AstraZeneca; Biothera; Clovis Oncology; Genentech; Genentech; Gensignia Life Sciences; Janssen; Lilly; Merck; Nektar
Research Funding - ACEA Biosciences (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Clovis Oncology (Inst); Janssen Oncology (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst)
 
Tony Mok
Employment - The Chinese University of Hong Kong
Leadership - Sanomics Limited
Stock and Other Ownership Interests - Cirina; Sanomics Limited
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Roche/Genentech
Consulting or Advisory Role - ACEA Biosciences; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Cirina; Clovis Oncology; geneDecode; Ignyta; Lilly; Merck Serono; Merck Sharp & Dohme; Novartis; Oncogenex; Pfizer; Roche/Genentech; SFJ Pharmaceuticals Group; Vertex
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Eisai (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); SFJ Pharmaceuticals Group (Inst); Taiho Pharmaceutical (Inst)
 
Yi-Long Wu
Honoraria - AstraZeneca; Boehringer Ingelheim; Lilly; Pfizer; Roche; Sanofi
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Merck; Roche
Research Funding - Boehringer Ingelheim (Inst); Roche (Inst)
 
Ji-Youn Han
Honoraria - Novartis
Consulting or Advisory Role - MSD Oncology
Research Funding - Roche
 
Myung-Ju Ahn
No Relationships to Disclose
 
Suresh S. Ramalingam
No Relationships to Disclose
 
Tom John
Honoraria - AstraZeneca/MedImmune; Bristol-Myers Squibb; Ignyta; MSD Oncology; Novartis; Pfizer; Pfizer; Roche/Genentech
Consulting or Advisory Role - AstraZeneca; AstraZeneca/MedImmune; Boehringer Ingelheim; Ignyta; MSD Oncology; Novartis; Pfizer; Roche/Genentech
Travel, Accommodations, Expenses - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Merck Sharp & Dohme; Roche; Roche
 
Martin Sebastian
No Relationships to Disclose
 
Willemijn Theelen
No Relationships to Disclose
 
Gianluca Laus
No Relationships to Disclose
 
Barbara Collins
Stock and Other Ownership Interests - AstraZeneca
Consulting or Advisory Role - AstraZeneca
 
Aleksandra Markovets
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Kenneth S. Thress
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Geoffrey R. Oxnard
Honoraria - Bio-Rad; Chugai Pharma; Guardant Health; Sysmex
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; DropWorks; Genentech/Roche; GRAIL; Ignyta; Inivata; LOXO; Novartis; Takeda
Patents, Royalties, Other Intellectual Property - DFCI has a patent pending titled "Non-invasive blood-based monitoring of genomic alterations in cancer", on which I am a co-author. (Inst)